One Amino Acid, Three High Stakes: What the Seventh Circuit's Pending Retatrutide Ruling Means for Exclusivity, Medicare Pricing, and Compounding Access

Key takeaways

• The US Seventh Circuit Court of Appeals heard oral argument on 24 September 2026 in Eli Lilly and Company v. Food and Drug Administration (No. 26-1301); no ruling had been published as of 10 October 2026.
• The case turns on whether retatrutide meets the FDA's regulatory definition of a "protein" — and therefore qualifies as a biological product subject to a Biologics License Application (BLA) — or whether it is a conventional drug subject to a New Drug Application (NDA).
• Classification as a biologic would extend regulatory exclusivity from five years to twelve, defer Medicare price-negotiation eligibility by four additional years under the Inflation Reduction Act, and permanently foreclose any pharmacy compounding pathway.
• Eli Lilly intends to file a BLA in the first quarter of 2027; the outcome of this appeal could require the company to switch to an NDA, potentially delaying the review clock.
• Retatrutide is not approved anywhere in the world and is not legally compoundable under any current regulatory framework, regardless of how the Seventh Circuit rules.

The molecule at the centre of the dispute

Retatrutide (LY3437943) is an investigational once-weekly injectable triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. It remains in Phase 3 trials and has not been submitted to the FDA for approval. It is an investigational triple-agonist (GLP-1/GIP/glucagon) obesity drug still in Phase 3 trials. Eli Lilly has confirmed it holds sufficient data to support filings for obesity, obstructive sleep apnoea, and knee osteoarthritis pain, and plans to submit an application in the first quarter of 2027.

From a clinical standpoint, the compound has attracted considerable attention. The molecule posted up to 30.3% average weight loss in TRIUMPH-1 — among the highest figures reported in any obesity trial to date. That clinical profile, combined with the breadth of potential indications, has led analysts to describe it as a major commercial asset. The resolution of its regulatory category therefore carries financial significance that extends well beyond a technical classification question.

How the FDA defines a protein — and where retatrutide sits

The FDA defines a protein as "any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size." The dispute centres on how the agency counts retatrutide's residues.

Retatrutide's structure runs to 41 residues, but the FDA counts only 40 of them as alpha amino acids — the remainder includes non-alpha-amino-acid components such as an ADO (8-amino-3,6-dioxaoctanoic acid) spacer. Count those out, and the molecule falls under the 40-residue threshold, which keeps it on the drug side of the regulatory boundary.

The FDA's definition of a protein is any alpha amino acid polymer with 40 or more amino acids. Retatrutide has 41 amino acids, according to Lilly's complaint. The FDA agreed that retatrutide is an alpha amino acid polymer and has a sequence of amino acids, but said it does not have 40 or more alpha amino acids. The therapy was classified as a drug.

There is a secondary argument: beyond the strict amino acid count, Lilly contends that retatrutide qualifies as something "analogous to a protein," a separate statutory hook that could also confer biologic status. A federal court in Indiana vacated the FDA's decision to regulate retatrutide as a "drug" rather than a "biological product," with Judge Tanya Walton Pratt ruling that the FDA's narrow reading of the statutory phrase "analogous to a protein" was arbitrary and capricious, and remanding the question back to the agency.

Lilly is not really fighting the vacatur — it wants the stronger remedy: a ruling that retatrutide must be classified as a biological product as a matter of law, rather than letting the FDA re-decide the "analogous" question on remand.

Where the appeal stands

On 24 September 2026, the Seventh Circuit heard oral argument in Eli Lilly and Company v. Food and Drug Administration. The question — what counts as a "protein" under the FDA's own regulation — determines whether retatrutide is regulated as a small-molecule-style drug or as a biologic, and that single classification reshapes exclusivity, competition, and compounding access for years.

Lilly's appeal was argued in the Seventh Circuit on September 24, 2026, and no decision had been published by October 10, 2026. The agency and the Department of Justice have contested Lilly's reading throughout, and the FDA argued that the lower court was correct in ruling that retatrutide was not a protein, but maintained that the 60-day limit applies only to the designation request, "not when a court vacates a designation decision."

Three commercial consequences that matter for procurement professionals

1. Regulatory exclusivity: five years versus twelve

The most financially significant consequence of the ruling is the length of market exclusivity. A BLA can provide 12 years of reference product exclusivity, compared with 5 years for a qualifying NDA. A licensed reference biologic can receive 12 years of reference-product exclusivity under the BPCI Act. A new chemical entity approved through an NDA typically receives five. That seven-year gap directly governs when biosimilar or generic competition can lawfully enter the market, and consequently the price trajectory that research buyers, health systems, and payers would face.

2. Medicare price negotiation: a four-year difference

Under the Inflation Reduction Act, drugs approved through NDAs become eligible for selection for Medicare price negotiation seven years after approval, versus eleven years for biologics, meaning negotiated prices take effect roughly nine and thirteen years after approval, respectively. The second consequential factor is Medicare price negotiation. Under the Inflation Reduction Act, small-molecule drugs become eligible for selection seven years after approval with negotiated prices taking effect at nine, while biologics are eligible at eleven years with prices effective at thirteen. For a compound with retatrutide's projected commercial scale, the difference in negotiation timing could represent material revenue over the life of the product.

3. Compounding: the door that may never open

For research-procurement professionals, the compounding implications are the most operationally immediate. Retatrutide cannot be legally compounded today: it has no applicable United States Pharmacopeia or National Formulary monograph, is not a component of an approved drug, and appears on neither the 503A nor 503B bulk substances list.

Compounding pathways under sections 503A and 503B of the FD&C Act do not extend to biological products the way they do to drugs. If retatrutide is ruled a biologic, the compounding lane narrows sharply and the originator holds the supply and the price for longer.

If retatrutide is licensed as a biologic under a BLA, the compounding door does not exist. There is no shortage exemption, no bulks list, no route. Compounded retatrutide would be legally impossible after approval, permanently. This contrasts with the drug pathway, under which a shortage declaration or bulks list placement could, in theory, open a compounding channel — though the experience with semaglutide and tirzepatide illustrates how constrained and contested such access becomes in practice.

Industry legal commentary has been unambiguous on the current state of play. Retatrutide is not approved and is not on FDA's compounding list, meaning it cannot legally be compounded today regardless of how the Seventh Circuit rules. One regulatory attorney noted that "companies that get hurt in periods like this usually are the ones that treat legal uncertainty, like we have right now, as permission, and it's not."

A grey market in purported retatrutide sold through "research-use only" channels has nonetheless been documented. A grey market of purported retatrutide is expanding via "research-use" channels, creating patient-safety and coverage challenges; FDA warning letters signal escalating enforcement. Lilly has filed lawsuits against compounders under state consumer protection and unfair competition laws rather than directly under the FDCA, a strategy that exposes companies to private damages claims, legal fees, and injunctive relief.

What to watch next

The Seventh Circuit's ruling, when it arrives, will either affirm the FDA's drug classification, direct the agency to classify retatrutide as a biologic as a matter of law, or return the matter to the lower court or the agency on one of the subsidiary questions. Each outcome has a different effect on the Q1 2027 filing timeline: if retatrutide is not a biologic, Lilly would have to file a New Drug Application instead of the one it has announced, which could delay approval.

Research-procurement teams sourcing GLP-1-class reference standards or investigational peptide APIs should note that the classification outcome will also influence how suppliers, compounders, and distributors frame access to retatrutide-adjacent material. The legal position as of October 2026 is unambiguous: the compound is investigational only, compounding is not permitted under any US regulatory framework, and enforcement is active. The Seventh Circuit ruling will determine the shape of the post-approval landscape — not the current one.

This briefing is based on publicly available court filings, FDA regulatory guidance, and published industry analysis. It does not constitute legal or procurement advice.